First human test for potential CMT1A treatment begins
NCT ID NCT07140614
Summary
This is the first study to test a new drug called EDK060 in people. It aims to check if the drug is safe and how it moves through the body in 28 adults with Charcot-Marie-Tooth disease type 1A (CMT1A). Participants will receive either the drug or a placebo, and researchers will closely monitor for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHARCOT-MARIE-TOOTH DISEASE TYPE 1A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
CIUSS de l´Estrie-CHUS- Hôpital Fleurimont
RECRUITINGSherbrooke, Quebec, J1H 5N4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Montreal Neurological Institute
RECRUITINGMontreal, Quebec, H3A 2B4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Novartis Investigative Site
RECRUITINGOttawa, Ontario, K1H 8L6, Canada
Conditions
Explore the condition pages connected to this study.